Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulixertinib in BRAF-mutated or BRAF-fused Advanced Cancers (MATCH Subprotocol Z1L)
NCT06400225Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ulixertinib in lymphoma, malignant solid neoplasm, multiple myeloma (MM), sponsored by National Cancer Institute. Started Jul 2019; status: active, not recruiting.
02
Drugs
ulixertinib
03
Conditions
lymphomamalignant solid neoplasmmultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06400225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06400225.